Margot Egger1, Benjamin Dieplinger1, Thomas Mueller2. 1. Department of Laboratory Medicine, Konventhospital Barmherzige Brueder Linz, Linz, Austria. 2. Department of Laboratory Medicine, Konventhospital Barmherzige Brueder Linz, Linz, Austria. Electronic address: thomas.mueller@bs-lab.at.
Abstract
BACKGROUND: We assessed the long-term in vitro stability of cardiac troponins and galectin-3 under different storage conditions. METHODS: We used high-sensitivity cardiac troponin I (hs-cTnI) and galectin-3 assays from Abbott and a high-sensitivity cardiac troponin T (hs-cTnT) assay from Roche. The analyte concentrations of 30 patients were measured in heparin-treated plasma, EDTA-treated plasma and serum samples after the following storage conditions: 1) samples used immediately after blood collection for baseline measurements; 2) samples stored for 0.5year at -80°C after one freeze-thaw cycle; 3) samples stored for 1.0year at -80°C after two freeze-thaw cycles; and 4) samples stored for 1.0year at -80°C after one freeze-thaw cycle. According to the concept of acceptable change limits (ACL) the analytes were considered stable as long as the median concentration at a particular time point was >80%. RESULTS: Baseline hs-cTnI, hs-cTnT and galectin-3 concentrations ranged from 2.3 to 5436ng/L, from 5.3 to 850ng/L, and from 8.3 to 79.3ng/mL, respectively. After applying the default criterion for analyte stability, the three analytes were stable for at least 1.0year even after two freeze-thaw cycles for each sample type. We observed the following variation in analyte concentrations after storage relative to the baseline values: the interquartile range (IQR) of cardiac troponin results extended from approx. 80 to 115%, and the IQR of galectin-3 results extended from approx. 90 to 110%. CONCLUSION: hs-cTnI, hs-cTnT and galectin-3 were stable under the reported storage conditions irrespective of the sample type used. However, we observed a considerable variation in analyte concentrations after sample storage, which might affect the diagnostic/prognostic value of these analytes in individual patients using frozen blood samples.
BACKGROUND: We assessed the long-term in vitro stability of cardiac troponins and galectin-3 under different storage conditions. METHODS: We used high-sensitivity cardiac troponin I (hs-cTnI) and galectin-3 assays from Abbott and a high-sensitivity cardiac troponin T (hs-cTnT) assay from Roche. The analyte concentrations of 30 patients were measured in heparin-treated plasma, EDTA-treated plasma and serum samples after the following storage conditions: 1) samples used immediately after blood collection for baseline measurements; 2) samples stored for 0.5year at -80°C after one freeze-thaw cycle; 3) samples stored for 1.0year at -80°C after two freeze-thaw cycles; and 4) samples stored for 1.0year at -80°C after one freeze-thaw cycle. According to the concept of acceptable change limits (ACL) the analytes were considered stable as long as the median concentration at a particular time point was >80%. RESULTS: Baseline hs-cTnI, hs-cTnT and galectin-3 concentrations ranged from 2.3 to 5436ng/L, from 5.3 to 850ng/L, and from 8.3 to 79.3ng/mL, respectively. After applying the default criterion for analyte stability, the three analytes were stable for at least 1.0year even after two freeze-thaw cycles for each sample type. We observed the following variation in analyte concentrations after storage relative to the baseline values: the interquartile range (IQR) of cardiac troponin results extended from approx. 80 to 115%, and the IQR of galectin-3 results extended from approx. 90 to 110%. CONCLUSION: hs-cTnI, hs-cTnT and galectin-3 were stable under the reported storage conditions irrespective of the sample type used. However, we observed a considerable variation in analyte concentrations after sample storage, which might affect the diagnostic/prognostic value of these analytes in individual patients using frozen blood samples.
Authors: Anahita Ghorbani; Vijeta Bhambhani; Robert H Christenson; Wouter C Meijers; Rudolf A de Boer; Daniel Levy; Martin G Larson; Jennifer E Ho Journal: J Am Coll Cardiol Date: 2018-12-25 Impact factor: 24.094
Authors: Mary R Rooney; Dan Wang; J William McEvoy; Stephen P Juraschek; John Chalmers; Mark Woodward; Elizabeth Selvin Journal: Diabetes Res Clin Pract Date: 2021-11-17 Impact factor: 5.602
Authors: Henning Jansen; Andrea Jaensch; Ben Schöttker; Dhayana Dallmeier; Roman Schmucker; Hermann Brenner; Wolfgang Koenig; Dietrich Rothenbacher Journal: J Am Heart Assoc Date: 2019-06-13 Impact factor: 5.501
Authors: Olena Iakunchykova; Maria Averina; Alexander V Kudryavtsev; Tom Wilsgaard; Andrey Soloviev; Henrik Schirmer; Sarah Cook; David A Leon Journal: J Am Heart Assoc Date: 2019-12-18 Impact factor: 5.501
Authors: David Aguilar; Caroline Sun; Ron C Hoogeveen; Vijay Nambi; Elizabeth Selvin; Kunihiro Matsushita; Anum Saeed; John W McEvoy; Amil M Shah; Scott D Solomon; Eric Boerwinkle; Christie M Ballantyne Journal: J Am Heart Assoc Date: 2020-06-23 Impact factor: 5.501
Authors: Olena Lakunchykova; Maria Averina; Tom Wilsgaard; Hugh Watkins; Sofia Malyutina; Yulia Ragino; Ruth H Keogh; Alexander V Kudryavtsev; Vadim Govorun; Sarah Cook; Henrik Schirmer; Anne Elise Eggen; Laila Arnesdatter Hopstock; David A Leon Journal: J Epidemiol Community Health Date: 2020-05-15 Impact factor: 3.710